2013-2020年物质使用障碍治疗机构尿液药物检测结果与过量死亡率的关联分析
该回顾性横断面研究纳入2013年1月1日至2020年12月31日期间由物质使用障碍治疗机构提交的50万份尿液标本,采用液相色谱-串联质谱检测可卡因、海洛因、甲基苯丙胺、合成阿片类和其他阿片类5类药物,并与CDC WONDER全国生命统计系统过量死亡数据做相关性分析。全国水平上合成阿片类和甲基苯丙胺与过量死亡率高度相关(Spearman ρ均为0.96)。州水平多变量分析中,尿液检测阳性率每增加1个标准差,合成阿片类月过量死亡增加16.2%(IRR 1.16;95%CI 1.14-1.19;P<.001),甲基苯丙胺增加11.7%(IRR 1.12;95%CI 1.09-1.14;P<.001),可卡因增加5.1%(IRR 1.05;95%CI 1.03-1.07;P<.001)。作者认为实时尿液药物检测监测可帮助快速识别药物使用模式变化,为针对性减少伤害策略提供信息。
要点
- 全国水平上合成阿片类和甲基苯丙胺的尿液检测阳性率与过量死亡率高度相关(Spearman ρ均为0.96)。
- 州水平多变量分析:尿液检测阳性率每增加1个标准差,合成阿片类月过量死亡增加16.2%(IRR 1.16;95%CI 1.14-1.19;P<.001)。
- 县水平多变量分析:合成阿片类IRR为1.13(95%CI 1.09-1.17;P<.001),即每1个标准差阳性率增加对应月过量死亡增加12.8%。
- 甲基苯丙胺(IRR 1.12;95%CI 1.09-1.14;P<.001)和可卡因(IRR 1.05;95%CI 1.03-1.07;P<.001)也与死亡率显著正相关,但效应量小于合成阿片类。
- 俄亥俄州县水平相关性以合成阿片类最强(ρ=0.71),其次为海洛因(ρ=0.69)和甲基苯丙胺(ρ=0.67)。
适用人群与场景
- 在物质使用障碍治疗机构提供尿液标本的18岁及以上成人。
- 标本提交时间为2013年1月1日至2020年12月31日。
研究设计与关键结果
- 研究类型:回顾性横断面研究;样本量:50万份尿液标本;人群:物质使用障碍治疗机构中18岁及以上成人;数据来源:Millennium Health专有全国数据库和CDC WONDER全国生命统计系统。
- 标本中288534份(57.7%)来自男性,研究人群中位年龄34岁(IQR,17-51岁)。
- 全国水平:合成阿片类和甲基苯丙胺与过量死亡率高度相关(Spearman ρ均为0.96)。
- 合成阿片类共同参与时,甲基苯丙胺(ρ=0.98)、海洛因(ρ=0.78)、可卡因(ρ=0.94)和其他阿片类(ρ=0.83)也与过量死亡率高度相关。
- 无合成阿片类参与时,其他阿片类(ρ=0.75)、海洛因(ρ=0.81)和甲基苯丙胺(ρ=0.88)高度相关,可卡因例外(ρ=-0.37)。
- 州水平随时间相关性最强:合成阿片类(ρ=0.77)和甲基苯丙胺(ρ=0.80);其他阿片类相关性最低,总阳性率ρ=0.31,无合成阿片类时阳性率ρ=0.23。
- 俄亥俄州县水平:合成阿片类ρ=0.71,海洛因ρ=0.69,甲基苯丙胺ρ=0.67。
- 州水平多变量IRR:合成阿片类1.16(95%CI,1.14-1.19;P<.001),即每1个标准差阳性率增加对应月过量死亡增加16.2%;甲基苯丙胺IRR 1.12(95%CI,1.09-1.14;P<.001),增加11.7%;可卡因IRR 1.05(95%CI,1.03-1.07;P<.001),增加5.1%。
证据类型、等级与局限
- 证据类型:回顾性横断面研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,实时尿液药物检测监测可帮助快速识别药物使用模式变化,为针对性减少伤害策略提供信息以预防过量死亡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Drug overdose deaths in the US are currently the highest ever recorded; data collected from public health surveillance sources can help to identify emerging drug use patterns associated with overdose mortality rates, but the time lag in results often limits utility. Urine drug testing (UDT) is one potentially underused source that could augment surveillance efforts through timely data collection.
OBJECTIVE: To evaluate the correlation between real-time UDT results from a proprietary national database and overdose mortality data from the National Vital Statistics System.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cross-sectional study included 500 000 urine specimens submitted for UDT by substance use disorder (SUD) treatment health care practices and collected between January 1, 2013, and December 31, 2020. Real-time UDT data were obtained from the Millennium Health proprietary national database, and overdose mortality data were obtained from the National Vital Statistics System of the Centers for Disease Control and Prevention (CDC WONDER). Specimens were analyzed for specific drugs in 5 categories (cocaine, heroin, methamphetamine, synthetic opioids, and other opioids) using liquid chromatography-tandem mass spectrometry. Participants were adults aged 18 years and older who provided urine specimens at SUD treatment practices.
EXPOSURES: Urine drug testing.
MAIN OUTCOMES AND MEASURES: The primary outcome was the correlation between UDT positivity rates and overdose mortality rates at national, state, and county levels. Univariate and multivariate regression models were also used to evaluate the association between state- and county-level overdose mortality and standardized UDT positivity rates.
RESULTS: Among 500 000 unique patient specimens collected from SUD treatment practices between 2013 and 2020, 288 534 specimens (57.7%) were from men, and the median age of the study population was 34 years (IQR, 17-51 years). On a national level, synthetic opioids and methamphetamine were highly correlated with overdose mortality (Spearman ρ = 0.96 for both). When synthetic opioids were coinvolved, methamphetamine (ρ = 0.98), heroin (ρ = 0.78), cocaine (ρ = 0.94), and other opioids (ρ = 0.83) were also highly correlated with overdose mortality. In the absence of synthetic opioids, all drug categories were highly correlated (ρ = 0.75 for other opioids, 0.81 for heroin, and 0.88 for methamphetamine), with the exception of cocaine (ρ = -0.37). Synthetic opioids (ρ = 0.77) and methamphetamine (ρ = 0.80) had the strongest state-level correlations over time, whereas other opioids had the lowest correlation for both total positivity (ρ = 0.31) and positivity in the absence of synthetic opioids (ρ = 0.23). In Ohio, county-level correlation was strongest for synthetic opioids (ρ = 0.71), followed by heroin (ρ = 0.69) and methamphetamine (ρ = 0.67). At the state level, the multivariate incidence rate ratio (IRR) for synthetic opioids was 1.16 (95% CI, 1.14-1.19; P < .001), and at the county level, the IRR was 1.13 (95% CI, 1.09-1.17; P < .001), suggesting that for every 1-SD increase in the UDT positivity rate, there were 16.2% and 12.8% increases, respectively, in monthly overdose deaths. Both methamphetamine (11.7% increase per 1-SD increase in UDT positivity rate; IRR, 1.12; 95% CI, 1.09-1.14; P < .001) and cocaine (5.1% increase per 1-SD increase in UDT positivity rate; IRR, 1.05; 95% CI, 1.03-1.07; P < .001) also had significant positive associations with mortality rates, but the effect sizes were smaller than that of synthetic opioids (IRR, 1.16).
CONCLUSIONS AND RELEVANCE: In this study, UDT results were highly correlated with mortality rates at national, state, and county levels. These findings suggest that real-time UDT surveillance can help to quickly identify changes in drug use patterns that might inform targeted harm reduction strategies designed to prevent overdose deaths.
参考来源
- Whitley P, LaRue L, Fernandez SA, et al. Analysis of Urine Drug Test Results From Substance Use Disorder Treatment Practices and Overdose Mortality Rates, 2013-2020. JAMA Netw Open. 2022. PMID: 35657623. doi:10.1001/jamanetworkopen.2022.15425
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。